Oxygen‑laden mesenchymal stem cells enhance the effect of gastric cancer chemotherapy in vitro

Zhou,Ya‑Li; Li,Yu‑Min; He,Wen‑Ting

doi:10.3892/ol.2018.9670

Oxygen‑laden mesenchymal stem cells enhance the effect of gastric cancer chemotherapy in vitro

Authors:
- Ya‑Li Zhou
- Yu‑Min Li
- Wen‑Ting He
View Affiliations

Affiliations: Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China, Key Laboratory of Digestive System Tumors, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China
Published online on: November 7, 2018 https://doi.org/10.3892/ol.2018.9670
Pages: 1245-1252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxia is an important factor that results in failure of chemotherapy for the majority of solid tumor types, particularly for gastric cancer. In the present study, mesenchymal stem cells (MSCs), which have the ability to migrate to cancer tissues were used as a vehicle to supply oxygen to gastric cancer. The hemoglobin genes were transfected into MSCs as MSC‑hemo groups. Subsequently, MSC‑hemo groups were induced by isopropyl‑b‑D‑thiogalactopyranoside and hemin to express hemoglobin. The hemoglobin was detected by western blotting method. Following this, the MSC‑hemo groups were placed in an atmosphere containing 100% oxygen and were used to investigate the effect of the function of the oxygen‑laden MSC‑hemo group on gastric cancer chemotherapy with an MTT assay. As a first approach to investigate the possibility of MSCs as a vehicle to supply oxygen to anoxic cancer types, including gastric, liver, breast cancer, the results indicated that the oxygen‑laden MSC‑hemo group significantly enhanced the effect of chemotherapeutic treatments on gastric cancer cells. Utilizing MSCs as a svehicle to supply oxygen to the solid tumor may be a novel method to improve the hypoxia conditions of tumor tissues and improve the effect of chemotherapy on tumor cells.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Power DG, Kelsen DP and Shah MA: Advanced gastric cancer-slow but steady progress. Cancer Treat Rev. 36:384–392. 2010. View Article : Google Scholar : PubMed/NCBI
3	Xuan Y, Hur H, Ham IH, Yun J, Lee JY, Shim W, Kim YB, Lee G, Han SU and Cho YK: Dichloroacetate attenuates hypoxia-induced resistance to 5-fluorouracil in gastric cancer through the regulation of glucose metabolism. Exp Cell Res. 321:219–230. 2014. View Article : Google Scholar : PubMed/NCBI
4	Willers H, Azzoli CG, Santivasi WL and Xia F: Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
5	Brown LM, Cowen RL, Debray C, Eustace A, Erler JT, Sheppard FC, Parker CA, Stratford IJ and Williams KJ: Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol Pharmacol. 69:411–418. 2006. View Article : Google Scholar : PubMed/NCBI
6	Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, Han S, Liu J, Sun S, Han Z, et al: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 99:121–128. 2008.PubMed/NCBI
7	Hao J, Song X, Song B, Liu Y, Wei L, Wang X and Yu J: Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther. 15:449–455. 2008. View Article : Google Scholar : PubMed/NCBI
8	Nardinocchi L, Puca R, Sacchi A and D'Orazi G: Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Mol Cancer. 8:12009. View Article : Google Scholar : PubMed/NCBI
9	Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 35:71–103. 2000. View Article : Google Scholar : PubMed/NCBI
10	Semenza GL: HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 8 (4 Suppl):S62–S67. 2002. View Article : Google Scholar : PubMed/NCBI
11	Mayer A and Vaupel P: Hypoxia, lactate accumulation, and acidosis: Siblings or accomplices driving tumor progression and resistance to therapy? Adv Exp Med Biol. 789:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wafik SE: Impact of genetic targets on cancer therapy. Springer; New York: 2013
13	Serakinci N, Fahrioglu U and Christensen R: Mesenchymal stem cells, cancer challenges and new directions. Eur J Cancer. 50:1522–1530. 2014. View Article : Google Scholar : PubMed/NCBI
14	Ren C, Kumar S, Chanda D, Chen J, Mountz JD and Ponnazhagan S: Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 26:2332–2338. 2008. View Article : Google Scholar : PubMed/NCBI
15	Li X, Lu Y, Huang W, Xu H, Chen X, Geng Q, Fan H, Tan Y, Xue G and Jiang X: In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol. 24:151–158. 2006. View Article : Google Scholar : PubMed/NCBI
16	Gao P, Ding Q, Wu Z, Jiang H and Fang Z: Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 290:157–166. 2010. View Article : Google Scholar : PubMed/NCBI
17	Seo SH, Kim KS, Park SH, Suh YS, Kim SJ, Jeun SS and Sung YC: The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther. 18:488–495. 2011. View Article : Google Scholar : PubMed/NCBI
18	Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, et al: Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 70:3718–3729. 2010. View Article : Google Scholar : PubMed/NCBI
19	Zhang B, Shan H, Li D, Li ZR, Zhu KS and Jiang ZB: The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma. Cancer Biol Ther. 13:1175–1184. 2012. View Article : Google Scholar : PubMed/NCBI
20	Chan WT, Verma CS, Lane DP and Gan SK: A comparison and optimization of methods and factors affecting the transformation of Escherichia coli. Biosci Rep. 33(pii): e000862013.PubMed/NCBI
21	Ji RC: Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett. 346:6–16. 2014. View Article : Google Scholar : PubMed/NCBI
22	Shannon AM, Bouchier-Hayes DJ, Condron CM and Toomey D: Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 29:297–307. 2003. View Article : Google Scholar : PubMed/NCBI
23	Bubnovskaya L, Osinsky D, Trachevsky V, Naleskina L, Kovelskaya A and Gumenyuk L: Premorphological alterations in gastric mucosa in patients with gastric cancer: Hypoxia level assessed by 31P NMR spectroscopy. Exp Oncol. 36:271–275. 2014.PubMed/NCBI
24	Höckel M and Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 93:266–276. 2001. View Article : Google Scholar : PubMed/NCBI
25	Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev. 13:139–168. 1994. View Article : Google Scholar : PubMed/NCBI
26	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
27	Nakamura J, Kitajima Y, Kai K, Hashiguchi K, Hiraki M, Noshiro H and Miyazaki K: HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. Int J Cancer. 127:1158–1171. 2010. View Article : Google Scholar : PubMed/NCBI
28	Di Caprio G, Stokes C, Higgins JM and Schonbrun E: Single-cell measurement of red blood cell oxygen affinity. Proc Natl Acad Sci USA. 12:9984–9989. 2015. View Article : Google Scholar
29	Dicato M, Duham C, Berchem G and Ries F: Clinical benefit from erythropoietin. Curr Opin Oncol. 12:297–302. 2000. View Article : Google Scholar : PubMed/NCBI
30	Väänänen HK: Mesenchymal stem cells. Ann Med. 37:469–479. 2005. View Article : Google Scholar : PubMed/NCBI
31	Murphy MB, Moncivais K and Caplan AI: Mesenchymal stem cells: Environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 45:e542013. View Article : Google Scholar : PubMed/NCBI
32	Loebinger MR, Kyrtatos PG, Turmaine M, Price AN, Pankhurst Q, Lythgoe MF and Janes SM: Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res. 69:8862–8867. 2009. View Article : Google Scholar : PubMed/NCBI
33	Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G, Figueiredo JL, Martuza RL, Weissleder R and Shah K: Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA. 106:4822–4827. 2009. View Article : Google Scholar : PubMed/NCBI
34	Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L and Zhu J: Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery. 65:610–624. 2009. View Article : Google Scholar : PubMed/NCBI
35	Tse WT, Pendleton JD, Beyer WM, Egalka MC and Guinan EC: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. Transplantation. 75:389–397. 2003. View Article : Google Scholar : PubMed/NCBI
36	Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V and Uccelli A: Human mesenchymal stem cells modulate B-cell functions. Blood. 107:367–372. 2006. View Article : Google Scholar : PubMed/NCBI
37	Tsimberidou AM: Targeted therapy in cancer. Cancer Chemother Pharmacol. 76:1113–1132. 2015. View Article : Google Scholar : PubMed/NCBI